0001415889-17-001907.txt : 20180109 0001415889-17-001907.hdr.sgml : 20180109 20171208142025 ACCESSION NUMBER: 0001415889-17-001907 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20171208 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VistaGen Therapeutics, Inc. CENTRAL INDEX KEY: 0001411685 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 205093315 STATE OF INCORPORATION: NV FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 343 ALLERTON AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-577-3600 MAIL ADDRESS: STREET 1: 343 ALLERTON AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Excaliber Enterprises, Ltd. DATE OF NAME CHANGE: 20070906 CORRESP 1 filename1.htm VistaGen Therapeutics, Inc. - FORM correspondence

 

Oppenheimer & Co. Inc.

85 Broad Street, 26th Floor

New York, NY 10004

December 8, 2017

 

 

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

 

 

 

Re:

VistaGen Therapeutics, Inc. (the “Company”)
Registration Statement on Form S-1 (File No. 333-221009)

 

Ladies and Gentlemen:

 

In connection with the above-captioned registration statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Oppenheimer & Co. Inc., as the representative of the underwriters, hereby joins in the request of the Company that the effective date of such registration statement be accelerated to 5:00 p.m. (New York time) on December 8, 2017, or as soon thereafter as practicable.

 

In making this request the undersigned acknowledges that the underwriters are aware of their obligations under the Act as they relate to the public offering of securities pursuant to the registration statement.

 

[Signature Page Follows]

 

 





Very truly yours,

 

OPPENHEIMER & CO. INC.
As the Representative of the Underwriters

 

 

By:

/s/ Eric Helenek

 

Name: 

Eric Helenek

 

Title:

Managing Director